[home] [Personal Program] [Help]

---

Session: Image Analysis - Cancer
Session starts: Friday 25 January, 13:00
Presentation starts: 13:30
Room: Lecture room 559

---

Martijn van de Giessen (Leiden University Medical Center/Delft University of Technology)
Bob Schaafsma (Leiden University Medical Center)
Judith Kroep (Leiden University Medical Center)
Martin Wasser (Leiden University Medical Center)
Cock van de Velde (Leiden University Medical Center)
Boudewijn Lelieveldt (Leiden University Medical Center/Delft University of Technology)
Jouke Dijkstra (Leiden University Medical Center)
Alexander Vahrmeijer (Leiden University Medical Center)

Abstract:
Neo-adjuvant chemotherapy response may be monitored in a non-invasive way using multi-spectral diffuse optical tomography (DOT) [1]. A clinically feasible measurement method in these 3D volumes is proposed and compared to previously published whole breast measurements [2]. Twelve breast cancer patients were included, which received neo-adjuvant chemotherapy. Four DOT scans were obtained: before therapy, after 3 and 9 weeks, and pre-operative (18 weeks). Deoxyhemoglobin (Hb), oxyhemoglobin (HbO2) and percentages water and lipids were measured in volumes as measured in DCE-MRI scans before therapy, centered on areas of high scattering amplitude and approximate location in pre-treatment DCE-MRI and/or X-ray mammography. Patients were divided in responders and poor responders based on post-operative pathological assessment. Responders (R) and poor responders (PR) showed statistically significant (P<0.05) different development of Hb values at 3, 9 and 18 weeks within measurement volumes relative to the first DOT scan: 0.66/1.08 (R/PR, 3 weeks), 0.56/1.07 (9 weeks), 0.55/1.48 (18 weeks). For HbO2 results were similar, but only significant for 9 and 18 weeks: 0.71/1.03 (3 weeks), 0.53/0.89 (9 weeks), 0.56/1.06 (18 weeks). Percentages water and lipids were not significantly different. Whole breast measurements did not show statistically significant differences for Hb and HbO2 between responders and poor responders. Using the scatter amplitude to determine the tumor location in DOT volumes enables the measurement of Hb and HbO2 such that these parameters differ significantly between responders and poor responders. This potentially allows effectiveness assessment of neo-adjuvant treatment in breast cancer patients already at 3 weeks. REFERENCES [1] S. Srinivasan, B.W. Pogue, et al: Data subset algorithm for computationally efficient reconstruction of 3-D spectral imaging in diffuse optical tomography, Optics Express, 2006 [2] O. Falou, H. Soliman, et al.: Diffuse optical spectroscopy evaluation of treatment response in women with locally advanced breast cancer receiving neoadjuvant chemotherapy, Translational Oncology, 2012